NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
Clinical Trials
14 trialsNCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT01630083 2025-06-15
FAST
Astellas Pharma Inc
Phase 2 Completed
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT06227117 2024-03-19
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02846428 2016-07-27
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed